Physician profile
Iris Gin
NPI 1588722680
$32,925.01
in general payments reported to CMS, 2019-2025
40 companies · $5,438 in 2025
The $5,438 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,124 · 2020: $2,320 · 2021: $3,897 · 2022: $4,819 · 2023: $5,461 · 2024: $7,865 · 2025: $5,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $395 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,266.83 |
| Education | $395.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,441.07 | 2019-2025 | |
| Janssen Biotech, INC. | $2,592.92 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $2,385.43 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $2,375.66 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $2,322.02 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Genzyme Corporation | $2,269.09 | 2019-2025 | |
| Pfizer INC. | $1,486.87 | 2019-2025 | |
| Leo Pharma INC. | $1,379.95 | 2020-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $1,331.49 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $1,135.82 | 2021-2025 | Opzelura, Opzelura |
| Musculoskeletal Transplant Foundation INC. | $1,122.79 | 2022 | |
| Allergan, INC. | $920.23 | 2019-2023 | |
| Journey Medical Corporation | $821.30 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $756.87 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $726.20 | 2019-2024 | Targretin, Arazlo, Cabtreo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $705.55 | 2019-2024 | Tremfya |
| Merz North America, INC. | $678.15 | 2019-2023 | Xeomin |
| Almirall LLC | $540.20 | 2019-2025 | Klisyri |
| Ucb, INC. | $498.29 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $488.10 | 2023-2024 | Vtama |
| Amgen INC. | $468.87 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $438.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $425.64 | 2022-2025 | Sotyktu |
| Revance Therapeutics, INC. | $399.82 | 2024-2025 | Daxxify, Daxi |
| Arcutis Biotherapeutics, INC. | $329.88 | 2023-2025 | Zoryve |
| Biofrontera INC. | $287.42 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Strata Skin Sciences, INC. | $280.99 | 2022-2025 | Xtrac |
| Celgene Corporation | $229.27 | 2019 | |
| Davol INC. | $192.67 | 2021 | |
| Dilon Technologies, INC. | $169.74 | 2025 | Hemoblast Bellows |
| Encore Dermatology INC. | $122.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.23 | 2021-2024 | |
| Epi Health, LLC | $119.01 | 2019-2021 | |
| Genentech USA, INC. | $112.09 | 2022-2023 | Xolair |
| Organon LLC | $67.05 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $57.50 | 2024-2025 | |
| Dermira, INC. | $52.87 | 2020-2021 | |
| Mission Pharmacal Company | $42.92 | 2019 | |
| Botanix Sb INC | $22.53 | 2025 | Sofdra |
| Pierre Fabre Pharmaceuticals, INC. | $6.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Gin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.